Citius, Altius, Fortius: An Olympian Dream for Theranostics.

We have recently witnessed the heroic efforts of athletes from around the world striving to achieve the Olympic motto— Faster, Higher, Stronger. This could equally be the catch-cry of radiochemists who seek to make tracers with faster synthesis times, higher yields, and stronger binding affinity to the target of choice. Rapid synthesis is particularly important for short-lived radionuclides such as 68Ga, and high yields are necessary to make tracers commercially viable. However, especially for agents that might become the diagnostic pair for a therapeutic agent, stronger binding to cellular targets is the ultimate goal. Radiochemistry is generally a team sport, with many important players. Most successful teams in the development of novel tracers have included a multidisciplinary team of biologists, pathologists, preclinical imaging scientists, chemists, and clinicians. Jean-Claude Reubi, Helmut Mäcke, and colleagues represent one of the eminent teams in receptor-based molecular imaging. In this edition of The Journal of Nuclear Medicine, this team describes the potential extension of